Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Unifirst CEO Ronald Croatti Was Buying At $91

Unifirst CEO: President and CEO of Unifirst Corp (NYSE:UNF) purchased 8,242 shares of common stock on Wednesday, at a price of $91 each. This acquisition required an investment of $750,022 and brought Ronald Croatti’s holdings up to 1,033,770 shares. Unifirst is now trading at 18.7 times its trailing earnings, meaning the stock is still available at a 29% price discount to the industry average. The stock has a dividend yield of 0.15% and is valued at $103.32 per share (as of Wednesday, Oct. 2, 3 pm EDT), which is just shy of its 52-week high of $104.76 per share. Croatti was able to purchase the shares at a discount price of $91 each, since he is also a 10% owner of the issuer, The Red Cat Limited Partnership.

UniFirst Corp

According to our records, this is the first acquisition of Unifirst made by Ronald Croatti. Hedge funds however, have been more active, as 15 of them are currently company shareholders. Royce & Associates is the largest, with 1,777,703 shares or approximately $162,215,000 worth of stock, amounting to 0.5% of its portfolio. First Eagle Investment Management , which is run by Jean-Marie Eveillard, is the second largest and holds 751,089 shares of common stock, making up for 0.2% of its portfolio. Both hedge funds, as well as CEO Croatti, were happy to see their stock climb by 0.30% following the insider purchase (as of Wednesday, Oct. 2, 3:26 pm EDT).

Unifirst is set to announce its fourth quarter results on October 23rd, before the market opens. The stock has been experiencing a strong upwards trend over the past year, which leads to believe the company will present strong results. The firm currently has an operating margin of 12%, which is far above the industry average of 4.7%. With analysts estimating an annual EPS growth of 6.7%, Croatti’s recent purchase seems to make sense.

Disclosure: Pablo Erbar holds no position in any stocks mentioned

Recommended Reading:

Capitala Finance’s IPO & The Insider Trade That Surrounded It

Pulaski Financial’s Board is Bullish

Daniel Ellis, Carmike Cinemas VP is Bullish

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!